We sought to identify distinct subgroups of men with high-risk localized prostate cancer who experience varying outcomes following treatment with a combination of high-dose contemporary radiation therapy and androgen-deprivation therapy (ADT). We found that patients with a single high-risk factor (favorable high-risk subgroup) had better outcomes than those with multiple high-risk factors (unfavorable high-risk subgroup) following treatment with a combination of external beam radiation therapy and ADT.
The favorable high-risk subgroup had a 5-year distant metastasis-free survival (88.0%) rate akin to patients with intermediate-risk prostate cancer (93.7%). The unfavorable high-risk subgroup had a 5-year distant metastasis-free survival rate (81.2%) more like patients with very high risk prostate cancer (78.4%).
These results highlight the heterogeneity within high-risk prostate cancer. This is one of the first series from Europe in patients with high-risk prostate cancer treated with radiotherapy that has sought to sub-classify high-risk disease. Further studies should consider the marked heterogeneity in this disease.
Read the Abstract
Written By: Daniel Cagney